This is a demo store. No orders will be fulfilled.

Garivulimab (anti-PD-L1) - Primary antibody, specific to CD274, >95% (SDS-PAGE&SEC), high purity, Human IgG1

    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • Host species: Human
  • Reactive species: Cynomolgus monkey,Human,Mouse
  • Isotype: Human IgG1
  • Conjugation: Unconjugated
In stock
Item Number
Ab182922
Grouped product items
SKU Size
Availability
Price Qty
Ab182922-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$109.90
Ab182922-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$519.90
Ab182922-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,399.90
Ab182922-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,239.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

Basic Description

Product Name Garivulimab (anti-PD-L1) - Primary antibody, specific to CD274, >95% (SDS-PAGE&SEC), high purity, Human IgG1
Synonyms B7 H antibody | B7 H1 antibody | B7 homolog 1 antibody | B7-H1 antibody | B7H antibody | B7H1 antibody | CD 274 antibody | CD-274 antibody | CD274 antibody | CD274 antigen antibody | CD274 molecule antibody | MGC142294 antibody | MGC142296 antibody | OTTH
Specifications & Purity Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA
Host species Human
Specificity CD274
Conjugation Unconjugated
Grade Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Product Description

Garivulimab (anti-PD-L1) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab (anti-PD-L1) selectively blocks the interaction of PD-L1 and PD-1. Garivulimab (anti-PD-L1) has antitumor activity.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg

Product Properties

Isotype Human IgG1
Light Chain Type kappa
SDS-PAGE 144.3 kDa
Purification Method Protein A purified
Purity >95% (SDS-PAGE&SEC)
Shape Liquid
Concentration See COA
Storage Temp Store at -80°C,Avoid repeated freezing and thawing
Shipped In Ice chest + Ice pads
Stability And Storage Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
CAS 2342597-81-1

Associated Targets(Human)

CD274 Tclin Programmed cell death 1 ligand 1 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Images

Garivulimab (anti-PD-L1) (Ab182922) - Flow Cytometry
Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling PD-L1 (red) with Garivulimab (anti-PD-L1) (Ab182922) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

Garivulimab (anti-PD-L1) (Ab182922) - ELISA
Immobilized Recombinant Human PD-L1 protein (rp199666) at 1.0 μg/mL can bind Garivulimab (anti-PD-L1) (Ab182922) with the EC50 of 69.29 ng/mL.

Garivulimab (anti-PD-L1) (Ab182922) - SEC
The purity of Garivulimab (anti-PD-L1) (Ab182922) is more than 95% verified by HPLC.

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Alternative Products

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.